Nubytide
Prevention and Treatment of Alzheimer's Disease
Pre-clinicalActive
Key Facts
Indication
Prevention and Treatment of Alzheimer's Disease
Phase
Pre-clinical
Status
Active
Company
About Cenna Biosciences
Cenna Biosciences is a preclinical-stage biotech targeting Alzheimer's Disease with its lead peptide drug, Nubytide, which employs a unique mechanism to inhibit Aß production and also addresses inflammation and Tau pathology. The company has secured a strong intellectual property position with multiple issued patents and recently received a $2.7M NIH Phase II SBIR grant to advance Nubytide towards an IND filing targeted for 2025. With a seasoned leadership team and a focus on a large, underserved market, Cenna is positioning itself as a potential disruptor in the AD therapeutic landscape, though it faces significant development and competitive risks inherent to the neurology space.
View full company profile